What it means
As an industry, biotechnology applies biology at the molecular level to solve problems in medicine, agriculture, and manufacturing. Drug developers engineer proteins and antibodies, design gene and cell therapies, and use genetic data to target diseases.
Agricultural firms develop seed traits for drought or pest resistance. Industrial biotech companies use enzymes and fermentation to make chemicals, fuels, and materials with lower environmental cost.
What defines biotech as an investment is its unusual risk shape. A typical drug company spends a decade and enormous sums moving a candidate through laboratory work and three phases of human trials, with most candidates failing along the way.
Value arrives in jumps: a successful trial result, a regulatory approval, or a takeover can multiply a small company's value in a day, while a failed trial can erase most of it just as fast. Many biotech firms have no revenue for years and survive on repeated funding rounds, partnerships, and milestone payments from larger pharmaceutical companies.
For managers and investors, the practical consequence is that biotech analysis is event-driven. Cash runway, trial timelines, patent life, and the probability of success at each development stage matter more than classic valuation ratios.
Diversification, through funds or baskets of companies, is the standard way to handle single-trial risk, and partnerships with big pharma often signal both validation and future funding. The sector's economics follow the drug-development pipeline with unusual purity.
Industry analyses put the cost of bringing one approved drug to market in the billions once failures are counted, and success rates climb step by step: only a minority of candidates entering human trials ever reach approval. That funnel explains the industry's structure.
Small firms carry the early, cheap, high-failure stages, then partner or sell to large pharmaceutical companies that can fund final trials and global launches, so acquisition announcements, not product launches, are often the real payday for early investors.
In practice
Real-world examples.
Example
A startup spends eight years developing an antibody treatment, burning through three funding rounds before a partnership with a large drugmaker funds its final trial phase. Each funding round came at a higher valuation as the trial milestones de-risked the programme.
Example
An agricultural biotech firm licenses a drought-tolerant seed trait to producers, earning royalties on every bag of seed sold. The firm needs no factories of its own, because partners multiply and distribute the seed while it collects a steady licence income.
Example
A biotech index fund spreads investor money across dozens of drug developers so that single trial failures barely dent overall returns. The fund's factsheet shows turnover is low, since the strategy is to hold through trial cycles rather than trade around them.
Formula
Calculation
No single formula applies. Analysts often use risk-adjusted net present value: rNPV = sum over stages of (probability of success at each stage x future cash flows, discounted), which weights pipeline value by trial success odds.
Worked example with invented probabilities. A drug candidate must pass three stages, with a 60% chance of passing the first, 35% the second and 60% the third.
- Chance of reaching approval = 0.60 x 0.35 x 0.60 = 0.126, or 12.6%.
- If an approved drug would be worth $800,000,000 today after discounting its future cash flows, the risk-weighted value is $800,000,000 x 0.126 = $100,800,000.
- Subtracting $30,000,000 of risk-weighted development costs gives an rNPV of $70,800,000.
The probabilities are illustrative and are not industry statistics.Case study
Seen in the real world.
This fictional, illustrative example follows Solstice Ventures, an invented fund that held twelve biotech positions, each small. One portfolio company, Genova Therapeutics, reported successful mid-stage trial results for its lead therapy and its value quadrupled in a week. Two others failed trials the same year and were written down almost to zero. Because Solstice had sized each position at a fraction of the fund and tracked cash runway and trial calendars for all twelve, the winners more than covered the losers, and the fund returned 22% for the year.
Its annual review attributed most of the return to two events, the trial success and one acquisition, which reinforced the diversification discipline. The fund also kept a rule that no position could exceed 10% of the fund at cost, so the worst possible loss from a single failed trial was limited to 10% of the fund. The fund, company and figures are invented.
Watch out
Common mistakes.
- Valuing early-stage biotech on earnings multiples when most such firms have no earnings; cash runway and pipeline probabilities are the relevant measures.
- Concentrating too much in one company, when single trial outcomes can destroy most of a position overnight.
- Ignoring patent timelines and regulatory milestones, which define how long a successful product can earn money before generic competition arrives.
Questions
People also ask.
How is biotech different from big pharma?
Biotech firms are usually smaller, research-driven companies built around biological platforms and pipelines, while big pharma runs large commercial portfolios, manufacturing, and global sales, often buying biotech innovations.
Why are biotech stocks so volatile?
Their value concentrates in a few binary events such as trial results and approval decisions, so a single announcement can multiply or wipe out most of a small company's worth.
What should a non-specialist look at before investing?
Cash runway, trial stage and timeline, patent protection, partnership quality, and position sizing, since diversification across many companies is the standard defence against trial failure. Even large biotech firms with real products swing sharply when a key trial or approval decision lands.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%